Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Enrollment open in phase II study of GI-6301 for chordoma

April 24, 2015

Ono Pharmaceutical requests squamous NSCLC indication for nivolumab

April 23, 2015

Tolerability, activity of antibody-drug conjugate SAR-408701 encourage clinical development

April 23, 2015

FDA assigns obinutuzumab orphan drug status for follicular lymphoma

April 22, 2015

FDA grants priority review to Adcetris supplemental BLA

April 22, 2015

Potent ADAM 17 antibody inhibits tumor growth

April 21, 2015

ZV-0201, an ADC for the treatment of HER2-positive cancers

April 21, 2015

Phase III study of Opdivo in NSCLC stopped early after meeting primary endpoint

April 20, 2015

Novel immunotherapy combination improves outcome in no-sq NSCLC patients

April 20, 2015

HER2-targeting ADC shows promise as a stable targeted therapeutic for multiple cancers

April 20, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...